TORONTO, Jan. 25, 2019 /CNW/ - David Elsley, President & CEO, Cardiol Therapeutics Inc. (CRDL), joined Loui Anastasopoulos, President, Capital Formation, Toronto Stock Exchange & TSX Venture Exchange, to close the market. Cardiol Therapeutics is a biotechnology company specializing in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. Cardiol Therapeutics Inc. commenced trading on Toronto Stock Exchange on December 20, 2018.

Cardiol Therapeutics Inc. Closes the Market (CNW Group/TMX Group Limited)

SOURCE TMX Group Limited

Copyright 2019 Canada NewsWire

Cardiol Therapeutics (TSX:CRDL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cardiol Therapeutics Charts.
Cardiol Therapeutics (TSX:CRDL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cardiol Therapeutics Charts.